Pages that link to "Q44695050"
Jump to navigation
Jump to search
The following pages link to Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients (Q44695050):
Displaying 50 items.
- Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders (Q26776151) (← links)
- New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity (Q26823090) (← links)
- Selection of induction therapy in kidney transplantation (Q26864234) (← links)
- Rabbit antithymocyte globulin induction therapy in adult renal transplantation (Q33373390) (← links)
- Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection (Q33385541) (← links)
- Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40 (Q34009025) (← links)
- Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development (Q34055699) (← links)
- Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts (Q34549740) (← links)
- Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection (Q34613091) (← links)
- Association of antibody induction immunosuppression with cancer after kidney transplantation (Q35513074) (← links)
- Successful Drug Development Despite Adverse Preclinical Findings Part 1: Processes to Address Issues and Most Important Findings (Q35603973) (← links)
- Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years (Q35776408) (← links)
- Cumulative Doses of T-Cell Depleting Antibody and Cancer Risk after Kidney Transplantation (Q35837585) (← links)
- Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States (Q35849150) (← links)
- Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens. (Q35935114) (← links)
- Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression (Q35973628) (← links)
- Incidence of malignancy after living kidney transplantation: a multicenter study from iran (Q36037651) (← links)
- Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials (Q36155850) (← links)
- Post-transplant lymphoproliferative disease: association with induction therapy? (Q36441441) (← links)
- Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients (Q36447876) (← links)
- Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation (Q36732580) (← links)
- Current concepts and perspectives of immunosuppression in organ transplantation (Q36798362) (← links)
- Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review (Q36830121) (← links)
- Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. (Q36985818) (← links)
- Risk of lymphoma subtypes after solid organ transplantation in the United States (Q37003308) (← links)
- HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort (Q37097738) (← links)
- The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways (Q37112443) (← links)
- Malignancy in kidney transplant recipients (Q37149427) (← links)
- Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies? (Q37561282) (← links)
- Antibody immunosuppressive therapy in solid-organ transplant: Part I. (Q37691180) (← links)
- Post-transplant malignancy: reducing the risk in kidney transplant recipients (Q37863680) (← links)
- Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment (Q37873950) (← links)
- Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review (Q37892707) (← links)
- UVA photosensitization of thiopurines and skin cancer in organ transplant recipients (Q37921124) (← links)
- Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation. (Q38009874) (← links)
- The role of Thymoglobulin induction in kidney transplantation: an update (Q38051718) (← links)
- Risk evaluation and mitigation strategies: a focus on belatacept (Q38085439) (← links)
- Malignancies: pre and post transplantation strategies. (Q38179658) (← links)
- Comparison of the incidence of de novo malignancy in liver or kidney transplant recipients: analysis of 2673 consecutive cases in a single center. (Q38445692) (← links)
- Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update (Q38456262) (← links)
- Renal cancer in kidney transplanted patients. (Q38552310) (← links)
- Use of polyclonal/monoclonal antibody therapies in transplantation (Q38769922) (← links)
- Comparative Effectiveness of Tacrolimus-Based Steroid Sparing versus Steroid Maintenance Regimens in Kidney Transplantation: Results from Discrete Event Simulation (Q38849979) (← links)
- Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation (Q38892578) (← links)
- Clinical pancreatic islet transplantation. (Q39005220) (← links)
- Iodine-125 prostate seed brachytherapy in renal transplant recipients: an analysis of oncological outcomes and toxicity profile (Q39029878) (← links)
- Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study (Q39386528) (← links)
- Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. (Q39450656) (← links)
- Clinical and Economic Consequences of Early Cancer After Kidney Transplantation in Contemporary Practice. (Q39525547) (← links)
- Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells (Q39776480) (← links)